TCGA-E2-A14Y-01A-21R-A12D-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 70
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.600
- E2F_TARGETS+0.580
- MYC_TARGETS_V2+0.580
- G2M_CHECKPOINT+0.530
- MTORC1_SIGNALING+0.530
- OXIDATIVE_PHOSPHORYLATION+0.510
- CHOLESTEROL_HOMEOSTASIS+0.450
- NOTCH_SIGNALING+0.430
- TNFA_SIGNALING_VIA_NFKB+0.410
- HYPOXIA+0.390
Top 10 suppressed
- MYOGENESIS-0.150
- APICAL_JUNCTION-0.130
- BILE_ACID_METABOLISM-0.130
- UV_RESPONSE_DN-0.090
- ALLOGRAFT_REJECTION-0.030
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.020
- DNA_REPAIR-0.010
- PROTEIN_SECRETION-0.010
- HEME_METABOLISM+0.030
- ANGIOGENESIS+0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6079985 | — | — | 0.869 |
| 2 | SRR35579811 | — | B | 0.868 |
| 3 | BS_1D6PZNKN | Diffuse intrinsic pontine glioma | — | 0.858 |
| 4 | TCGA-51-4079-01A-01R-1100-07 | — | cohortSQ2 | 0.836 |
| 5 | SRR1313157 | — | E | 0.836 |
| 6 | TCGA-60-2723-01A-01R-0851-07 | — | cohortSQ2 | 0.834 |
| 7 | BS_SHJA4MR0 | high-grade glioma | — | 0.831 |
| 8 | SRR8518164 | — | E | 0.831 |
| 9 | SRR1313147 | — | E | 0.829 |
| 10 | TCGA-G2-A2ES-01A-11R-A180-07 | — | — | 0.829 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.600 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.580 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.580 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.530 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.530 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.510 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.450 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.430 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.410 | Inavolisib | — uncovered |
| HYPOXIA | 0.390 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.370 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.320 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.320 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.290 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.270 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.260 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.260 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.250 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.240 | Inavolisib | — uncovered |